Changes of Mean Health Utility Scores Throughout the Study Period by Participant Group

Online Resource 3:

Changes of mean health utility scores throughout the study period by participant group

Title: The impact of tuberculosis on health utility: a longitudinal cohort study

Journal: Quality of Life Research

Authors and affiliations

Melissa Bauer, MPH1, 2, Sara Ahmed, PhD3, Andrea Benedetti, PhD1, 2, Christina Greenaway, MD, MSc4,

Marek Lalli, MSc1, Allison Leavens, BSc1, Dick Menzies, MD, MSc1, Claudia Vadeboncoeur, MSPH1,

Bilkis Vissandjée, PhD5, Ashley Wynne, MSc1, Kevin Schwartzman, MD, MPH1

1 McGill University, Respiratory Epidemiology and Clinical Research Unit, Montreal, Canada

2 McGill University, Department of Epidemiology, Biostatistics, and Occupational Health, Montreal, Canada

3 McGill University Health Center, Division of ClinicalEpidemiology, Montreal, Canada

4 Sir Mortimer B. Davis – Jewish General Hospital, Division of Infectious Diseases and Clinical Epidemiology, Montreal, Canada

5 Université de Montréal, Faculté des sciences infirmières – School of Nursing, Montreal, Canada

Corresponding author – Email:

Online Resource 3 - Table 1. Changes in mean SF-6D health utility scores reported since the baseline visit for each follow-up interval by participant group

Time Interval / Crude Estimate / Adjusted Estimatea / 95%
Confidence Interval
Adjusted Estimate / P-value *
Baseline to 1 month of treatment
Tuberculosis disease / +0.08 / +0.08 / +0.04, +0.12 / 0.01*
Latent tuberculosis infection / -0.02 / -0.02 / -0.05, +0.01 / 0.07
Controlb / 0.00 / +0.02 / -0.01, +0.05 / --
Baseline to 2 months of treatment
Tuberculosis disease / +0.13 / +0.13 / +0.09, +0.16 / <0.0001*
Latent tuberculosis infection / -0.02 / -0.02 / -0.04, +0.01 / 0.37
Control / 0.00 / 0.00 / -0.03, +0.02 / --
Baseline to 4 months of treatment
Tuberculosis disease / +0.12 / +0.12 / +0.09, +0.16 / <0.0001*
Latent tuberculosis infection / -0.02 / -0.02 / -0.04, +0.01 / 0.07
Control / 0.00 / +0.02 / -0.01, +0.04 / --
Baseline to 6 months of treatment
Tuberculosis disease / +0.13 / +0.13 / +0.09, +0.16 / <0.0001*
Latent tuberculosis infection / -0.02 / -0.02 / -0.04, +0.01 / 0.11
Control / 0.00 / +0.01 / -0.02, +0.04 / --
Baseline to 9 months of treatment
Tuberculosis disease / +0.18 / +0.19 / +0.15, +0.22 / <0.0001*
Latent tuberculosis infection / -0.03 / -0.03 / -0.08, +0.03 / 0.07
Control / 0.00 / +0.01 / -0.02, +0.04 / --
Baseline to 12 months of treatment
Tuberculosis disease / +0.18 / +0.18 / +0.14, +0.22 / <0.0001*
Latent tuberculosis infection / 0.00 / -0.01 / -0.03, +0.02 / 0.15
Control / +0.01 / +0.02 / -0.01, +0.06 / --

a Adjusted models comparing participants treated for TB disease to those participants in the untreated control group controlled for age at baseline, sex, student status at baseline (student/not a student), and other health problems (yes/no) reported by participants at baseline. Adjusted models comparing participants treated for LTBI to those participants in the untreated control group controlled for age at baseline, sex, other health problems (yes/no), and number of days of work or school missed due to diagnosis and treatment of condition.

b Control is a participant screened for TB who tested negative for TB and was found not to require treatment.

* Indicates a p-value less than 0.05 meaning a statistically significant difference in the change in mean SF-6D scores from the baseline visit to each follow-up visit as reported by the group of treated participants and the participants in the untreated control group in the adjusted model.

Online Resource 3 – Table 2. Changes in mean SF-6D health utility scores reported at each follow-up interval by participant group

Time Interval / Crude Estimate / Adjusted Estimate a / 95%
Confidence Interval
Adjusted Estimate / P-value *
Baseline to 1 month of treatment
Tuberculosis disease / +0.08 / +0.08 / +0.04, +0.12 / 0.01*
Latent tuberculosis infection / -0.02 / -0.02 / -0.05, +0.01 / 0.07
Controlb / 0.00 / +0.02 / -0.01, +0.05 / --
1 to 2 months of treatment
Tuberculosis disease / +0.05 / +0.05 / +0.01, +0.09 / 0.07
Latent tuberculosis infection / 0.00 / 0.00 / -0.03, +0.03 / 0.29
Control / -0.01 / -0.02 / -0.05, +0.01 / --
2 to 4 months of treatment
Tuberculosis disease / 0.00 / 0.00 / -0.05, +0.04 / 0.40
Latent tuberculosis infection / 0.00 / 0.00 / -0.05, +0.05 / 0.44
Control / 0.00 / +0.02 / -0.02, +0.05 / --
4 to 6 months of treatment
Tuberculosis disease / +0.01 / 0.00 / -0.04, +0.05 / 0.82
Latent tuberculosis infection / 0.00 / 0.00 / -0.03, +0.04 / 0.97
Control / 0.00 / 0.00 / -0.04, +0.04 / --
6 to 9 months of treatment
Tuberculosis disease / +0.05 / +0.06 / +0.01, +0.11 / 0.03*
Latent tuberculosis infection / -0.01 / -0.01 / -0.05, +0.02 / 0.97
Control / -0.01 / -0.01 / -0.05, +0.03 / --
9 to 12 months of treatment
Tuberculosis disease / 0.00 / 0.00 / -0.05, +0.05 / 0.53
Latent tuberculosis infection / +0.02 / +0.02 / -0.01, +0.06 / 0.82
Control / +0.02 / +0.02 / -0.02, +0.06 / --

b Control is a participant screened for TB who tested negative for TB and was found not to require treatment.

* Indicates a p-value of less than 0.05 meaning a statistically significant difference in the change in mean SF-6D scores from between successive visits as reported by the group of treated participants and the participants in the untreated control group in the adjusted model.

Online Resource 3 - Table 3. Changes in mean Standard Gamble health utility scores reported since the

baseline visit for each follow-up interval by participant group

Time Interval / Crude Estimate / Adjusted Estimate a / 95%
Confidence Interval
Adjusted Estimate / P-value*
Baseline to 1 month of treatment
Tuberculosis disease / +0.15 / +0.15 / +0.10, +0.21 / < 0.0001*
Latent tuberculosis infection / -0.03 / -0.03 / -0.08, +0.01 / 0.54
Controlb / -0.02 / -0.02 / -0.06, +0.02 / --
Baseline to 2 months of treatment
Tuberculosis disease / +0.15 / +0.15 / +0.10, +0.21 / < 0.0001*
Latent tuberculosis infection / -0.03 / -0.03 / -0.06, +0.01 / 0.53
Control / -0.05 / -0.05 / -0.09, -0.01 / --
Baseline to 4 months of treatment
Tuberculosis disease / +0.14 / +0.15 / +0.09, +0.21 / < 0.0001*
Latent tuberculosis infection / -0.03 / -0.03 / -0.07, +0.01 / 0.90
Control / -0.03 / -0.03 / -0.07, +0.01 / --
Baseline to 6 months of treatment
Tuberculosis disease / +0.17 / +0.18 / +0.12, +0.24 / < 0.0001*
Latent tuberculosis infection / 0.00 / 0.00 / -0.04, +0.04 / 0.52
Control / -0.02 / -0.02 / -0.06, +0.02 / --
Baseline to 9 months of treatment
Tuberculosis disease / +0.21 / +0.22 / +0.16, +0.28 / < 0.0001*
Latent tuberculosis infection / +0.01 / +0.01 / -0.03, +0.05 / 0.16
Control / -0.04 / -0.04 / -0.08, +0.01 / --
Baseline to 12 months of treatment
Tuberculosis disease / +0.26 / +0.27 / +0.20, +0.33 / < 0.0001*
Latent tuberculosis infection / +0.02 / +0.02 / -0.02, +0.06 / 0.48
Control / 0.00 / 0.00 / -0.05, +0.04 / --

a Adjusted models comparing participants treated for TB disease to those participants in the untreated control group controlled for age at baseline, sex, and number of individuals residing in the participants’ households. Adjusted models comparing participants treated for LTBI to those participants in the untreated control group controlled for age at baseline, sex, student status at baseline (student/not a student), and participants’ personal income as a percentage of total household income (participants’ income as 0-19%, 20-39%, 40-59%, 60-79%, or 80-100% of total household income).

b Control is a participant screened for TB who tested negative for TB and was found not to require treatment.

* Indicates a p-value less than 0.05 meaning a statistically significant difference in the change in mean Standard Gamble scores from the baseline visit to each follow-up visit as reported by the group of treated participants and the participants in the untreated control group in the adjusted model.

Online Resource 3 - Table 4. Changes in mean Standard Gamble health utility scores reported at each follow-up interval by participant group

Time Interval / Crude Estimate / Adjusted Estimate a / 95%
Confidence Interval
Adjusted Estimate / P-value*
Baseline to 1 month of treatment
Tuberculosis disease / +0.15 / +0.15 / +0.10, +0.21 / < 0.0001*
Latent tuberculosis infection / -0.03 / -0.03 / -0.08, +0.01 / 0.54
Controlb / -0.02 / -0.02 / -0.06, +0.02 / --
1 to 2 months of treatment
Tuberculosis disease / 0.00 / 0.00 / -0.06, +0.06 / 0.43
Latent tuberculosis infection / +0.01 / +0.01 / -0.04, +0.05 / 0.25
Control / -0.03 / -0.03 / -0.07, +0.01 / --
2 to 4 months of treatment
Tuberculosis disease / -0.01 / 0.00 / -0.06, +0.05 / 0.63
Latent tuberculosis infection / -0.01 / 0.00 / -0.05, +0.04 / 0.55
Control / +0.01 / +0.01 / -0.03, +0.06 / --
4 to 6 months of treatment
Tuberculosis disease / +0.03 / +0.03 / -0.03, +0.09 / 0.64
Latent tuberculosis infection / +0.03 / +0.03 / -0.02, +0.09 / 0.55
Control / +0.01 / +0.01 / -0.04, +0.06 / --
6 to 9 months of treatment
Tuberculosis disease / +0.03 / +0.04 / -0.02, +0.09 / 0.15
Latent tuberculosis infection / 0.00 / 0.00 / -0.05, +0.06 / 0.57
Control / -0.03 / -0.02 / -0.06, +0.03 / --
9 to 12 months of treatment
Tuberculosis disease / +0.05 / +0.05 / -0.02, +0.12 / 0.68
Latent tuberculosis infection / +0.01 / +0.01 / -0.04, +0.07 / 0.61
Control / +0.03 / +0.03 / -0.02, +0.08 / --

b Control is a participant screened for TB who tested negative for TB and was found not to require treatment.

* Indicates a p-value of less than 0.05 meaning a statistically significant difference in the change in mean Standard Gamble scores from between successive visits as reported by the group of treated participants and the participants in the untreated control group in the adjusted model.